Summary

The global Live Attenuated Veterinary Vaccines market is projected to grow from US$ 6559 million in 2025 to US$ 10600 million by 2032, at a CAGR of 7.1% (2026-2032), driven by critical product segments and diverse end‑use applications.
Live Attenuated Veterinary Vaccines are biological preparations containing living microorganisms that have been weakened through controlled attenuation processes while retaining their ability to stimulate protective immune responses in animals. These vaccines typically use attenuated viral, bacterial, or parasitic strains that can undergo limited replication or biological development in the host without causing the full clinical manifestations associated with their virulent counterparts when administered under approved conditions. Attenuation may be achieved through serial passage, adaptation to specific culture conditions, selection of naturally attenuated strains, or established molecular techniques. Their principal function is to induce antigen-specific immunity, including humoral and cellular immune responses, against infectious animal diseases. Commercial products are generally formulated as freeze-dried, liquid, or frozen preparations, with their biological activity and stability maintained through validated manufacturing, storage, and administration procedures. Live attenuated veterinary vaccines are used in preventive animal healthcare programs to reduce disease incidence, clinical severity, pathogen circulation, and associated production losses.
Key Findings
Live Attenuated Veterinary Vaccines are an established category of preventive biological products used across livestock and companion animal healthcare
Live Attenuated Veterinary Vaccines commonly induce both humoral and cellular immune responses through controlled exposure to attenuated microorganisms
Poultry live attenuated vaccines represent a major commercial segment supported by routine flock immunization programs
Swine live attenuated vaccines are important for managing selected infectious diseases in intensive pig production systems
Freeze-dried live attenuated veterinary vaccines are widely used where biological stability and practical distribution are essential
Market Trends
The Live Attenuated Veterinary Vaccines industry is evolving from conventional disease-specific immunization toward more integrated preventive healthcare programs emphasizing vaccine effectiveness, biological consistency, administration efficiency, and compatibility with modern animal production systems. Advances in attenuation technologies, seed strain characterization, molecular diagnostics, and manufacturing quality control are improving the development and evaluation of vaccine candidates. In poultry production, vaccination strategies increasingly emphasize hatchery-level administration, mass immunization, and synchronization with flock management schedules. Swine producers are placing greater emphasis on vaccination protocols that account for pathogen circulation, maternal antibodies, herd immunity, and production-stage differences. Meanwhile, companion animal vaccination continues to prioritize established protective immunity, product safety, and practical vaccination schedules. Product development is also increasingly influenced by the need for reliable cold-chain management, improved formulation stability, and administration methods that reduce labor requirements. Over the longer term, manufacturers are expected to focus on balancing immunogenicity, attenuation stability, and operational convenience while supporting increasingly sophisticated veterinary disease prevention systems.
Market Dynamics
Drivers
Demand for live attenuated veterinary vaccines is supported by the economic consequences of infectious animal diseases and the growing importance of preventive veterinary medicine in commercial livestock production. Intensive poultry and swine farming creates operational incentives to maintain herd and flock health, minimize mortality, protect feed conversion efficiency, and reduce interruptions to production cycles. Vaccination programs for diseases such as Newcastle disease, infectious bronchitis, infectious bursal disease, and selected swine viral infections provide recurring demand where approved live attenuated products are incorporated into veterinary protocols. Increasing attention to animal health management, veterinary supervision, and the prevention of avoidable production losses further supports vaccine procurement. In companion animals, established vaccination recommendations and routine veterinary healthcare contribute to continuing demand for appropriate live attenuated products.
Restraints
The market faces constraints associated with the biological characteristics of live vaccines, particularly their sensitivity to environmental conditions, dependence on appropriate storage, and requirements for careful administration. Maintaining viability during manufacturing, transportation, and field application can increase operational complexity compared with certain nonliving vaccine formulations. Maternal antibody interference, pre-existing immunity, and differences between vaccine strains and circulating pathogens may influence field performance. Some attenuated vaccines also have restrictions relating to animal health status, reproductive condition, immunocompetence, or epidemiological circumstances. These considerations can limit product suitability in particular vaccination programs and increase the importance of veterinary guidance. In addition, regulatory requirements for demonstrating safety, potency, genetic stability, and manufacturing consistency can increase development costs and prolong commercialization timelines.
Opportunities
Commercial opportunities are emerging from improvements in vaccine delivery systems, formulation stability, and disease-specific immunization strategies. Hatchery vaccination, drinking-water administration, and other flock-level delivery approaches can create demand for products that maintain biological activity under practical operating conditions. In swine production, vaccine manufacturers can develop more differentiated offerings by addressing regionally relevant pathogens, improving compatibility with herd vaccination schedules, and providing technical support for disease management programs. The development of combination vaccines and improved stabilizing formulations may also enhance customer convenience where supported by product compatibility and regulatory approval. In emerging livestock markets, expanding veterinary infrastructure, improved disease surveillance, and the professionalization of farm management may support broader adoption of structured immunization programs. Suppliers capable of combining validated vaccine performance with dependable distribution and field-level technical services are positioned to access additional customers and recurring procurement opportunities.
Challenges
Long-term industry challenges center on maintaining the appropriate balance between vaccine attenuation, protective efficacy, and biological safety. Live attenuated organisms require rigorous evaluation of genetic stability, potential residual virulence, shedding characteristics, and suitability for different animal populations. The emergence of new pathogen variants and changes in regional disease epidemiology can complicate vaccine strain selection and require periodic reassessment of vaccination strategies. Field effectiveness may also be affected by inconsistent administration, inadequate cold-chain practices, concurrent infections, and variable farm biosecurity. Manufacturers must manage these technical uncertainties while meeting evolving regulatory expectations and controlling production costs. Competitive pressure from inactivated, recombinant, and other vaccine technologies may further influence product selection, particularly in applications where safety considerations, diagnostic differentiation, or vaccination logistics favor alternative approaches.
Industry Chain Analysis
The Live Attenuated Veterinary Vaccines industry chain comprises upstream biological materials and production inputs, midstream vaccine development and manufacturing, and downstream veterinary distribution and immunization services. Upstream activities involve the development and maintenance of attenuated seed strains, cell substrates, embryonated eggs, culture media, stabilizers, pharmaceutical-grade excipients, and specialized manufacturing consumables. Biological seed quality, substrate suitability, and raw material consistency directly affect vaccine potency, production yield, and batch reproducibility. Midstream manufacturing typically involves seed lot management, controlled biological propagation, harvesting, formulation, filling, and product-specific stabilization processes, including lyophilization where appropriate. Quality control focuses on identity, purity, potency, safety, and stability, supported by validated production procedures and contamination prevention systems.
Downstream channels include veterinary pharmaceutical distributors, livestock production enterprises, hatcheries, breeding operations, veterinary clinics, and animal health service providers. Value creation extends beyond vaccine production to include regulatory registration, disease-specific technical expertise, cold-chain logistics, administration guidance, and post-market monitoring. Manufacturing economics are influenced by biological production yields, batch release requirements, quality assurance expenditure, and distribution losses associated with temperature-sensitive products. Established manufacturers can benefit from validated production platforms and established distribution networks, while specialized suppliers may compete through disease-focused portfolios, regional registrations, and customer-specific vaccination support. Reliable field performance and continuity of supply are particularly important in securing repeat purchases from large livestock producers.
Segment Insights
By biological origin, Live Attenuated Veterinary Vaccines are divided into live attenuated viral vaccines, bacterial vaccines, and parasitic vaccines. Viral vaccines constitute a commercially important category because of their extensive application in poultry, swine, and companion animal immunization programs. Products targeting Newcastle disease, infectious bronchitis, infectious bursal disease, and selected swine viral diseases illustrate the importance of disease-specific strain selection, immunogenicity, and administration compatibility. Live attenuated bacterial vaccines serve more specialized disease prevention requirements, while attenuated parasitic vaccines are relevant in selected applications such as poultry coccidiosis control. Product differentiation is primarily determined by protective efficacy, biological safety, strain characteristics, and compatibility with farm vaccination protocols rather than by antigen composition alone.
By target animal species, poultry and swine vaccines represent strategically important commercial segments because vaccination is closely integrated with intensive production cycles. Poultry vaccines benefit from standardized flock management, recurring immunization schedules, and the operational advantages of mass administration. Swine vaccines require greater attention to herd infection status, animal age, maternal immunity, and disease-specific vaccination timing. From a formulation perspective, freeze-dried vaccines remain widely used because stabilization can support storage and distribution of viable biological materials, while liquid and frozen formulations serve applications with different stability and handling requirements. Monovalent, multivalent, and combined vaccine products address different immunization needs, although combination development requires evidence of antigen compatibility and adequate protective responses. Manufacturers can create additional value through improved formulation stability, consistent vaccine potency, validated combination products, and delivery systems adapted to commercial farm operations.
Downstream Market Opportunities
Commercial poultry farming and poultry breeding operations are major downstream applications for Live Attenuated Veterinary Vaccines. Vaccination is commonly integrated into hatchery operations, broiler production, and layer or breeder management to protect against infectious diseases that can cause mortality, respiratory disorders, immunosuppression, and productivity losses. Depending on the product and approved protocol, live vaccines may be administered by spray, drinking water, ocular application, or other designated routes. Hatcheries and large poultry producers prioritize vaccine uniformity, administration throughput, biological stability, and compatibility with existing vaccination equipment. Commercial opportunities arise from products designed for efficient flock-level administration, improved stability during preparation and application, and technical programs that support consistent vaccination outcomes across production sites.
Swine farming represents another important application, particularly where live attenuated vaccines are incorporated into programs addressing porcine reproductive and respiratory syndrome and other relevant infectious diseases. Swine producers evaluate vaccine products according to protective performance, safety, herd disease status, and compatibility with breeding and production schedules. Dairy and beef cattle operations, sheep and goat farms, and equine breeding enterprises provide additional disease-specific opportunities where suitable products are registered and recommended. In companion animal veterinary care, live attenuated vaccines are used in established preventive programs against selected canine and feline infectious diseases, with veterinary clinics emphasizing safety, protective immunity, and adherence to recommended schedules. Across these applications, manufacturers can strengthen commercial relationships through disease-specific product portfolios, dependable supply, veterinary training, and vaccination support services.
Regional Insights
North America and Europe are established markets for Live Attenuated Veterinary Vaccines, supported by developed veterinary healthcare systems, commercial livestock operations, established vaccine manufacturers, and structured regulatory frameworks. North American demand is influenced by intensive poultry and swine production, companion animal healthcare expenditure, and the integration of vaccination into broader veterinary management programs. European demand reflects advanced animal health management practices, established veterinary distribution channels, and regulatory requirements for biological product quality and safety. Product opportunities differ between countries according to animal populations, disease epidemiology, vaccination recommendations, and authorization status. Manufacturers operating in these regions increasingly compete through product reliability, technical services, and portfolio coverage rather than vaccine availability alone.
Asia-Pacific represents a particularly important market for commercial expansion because of its substantial poultry and swine production base, diverse infectious disease challenges, and continuing development of veterinary healthcare infrastructure. China and India have extensive domestic vaccine manufacturing capabilities and large livestock industries, while other Asian markets offer opportunities linked to commercial farming and disease prevention investment. Latin America also provides demand from poultry, cattle, and swine production, with vaccination requirements shaped by regional disease conditions and agricultural export considerations. In the Middle East and Africa, market development is influenced by veterinary service accessibility, cold-chain infrastructure, livestock production practices, and government-supported disease control programs. Regional expansion opportunities are therefore closely associated with local product registration, epidemiological relevance, distribution reliability, and the ability to adapt vaccination programs to different production environments.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Live Attenuated Veterinary Vaccines market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck
Zoetis
Boehringer Ingelheim
Ceva
CAHIC
HVRI
Ringpu Biology
Yebio
DHN
WINSUN
Elanco
Virbac
Jinyu Bio-Technology
ChengDu Tecbond
CAVAC
Kyoto Biken Laboratories
FATRO
Vaksindo
Bio-Labs
Avimex Animal Health
MEVAC
Biovac
Atafen
Dyntec
RVSRI
Medion
Segment by Type
Live Attenuated Viral Vaccines
Live Attenuated Bacterial Vaccines
Other
Segment by Dosage Form
Freeze-Dried Live Attenuated Vaccines
Liquid Live Attenuated Vaccines
Frozen Live Attenuated Vaccines
Segment by Vaccine Combination
Monovalent Vaccines
Multivalent Vaccines
Combination Vaccines
Segment by Application
Farm Animal
Companion Animal
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Live Attenuated Veterinary Vaccines study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Live Attenuated Veterinary Vaccines: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Live Attenuated Veterinary Vaccines Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Live Attenuated Viral Vaccines
1.2.3 Live Attenuated Bacterial Vaccines
1.2.4 Other
1.3 Market Segmentation by Dosage Form
1.3.1 Global Live Attenuated Veterinary Vaccines Market Size by Dosage Form, 2021 vs 2025 vs 2032
1.3.2 Freeze-Dried Live Attenuated Vaccines
1.3.3 Liquid Live Attenuated Vaccines
1.3.4 Frozen Live Attenuated Vaccines
1.4 Market Segmentation by Vaccine Combination
1.4.1 Global Live Attenuated Veterinary Vaccines Market Size by Vaccine Combination, 2021 vs 2025 vs 2032
1.4.2 Monovalent Vaccines
1.4.3 Multivalent Vaccines
1.4.4 Combination Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Live Attenuated Veterinary Vaccines Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Farm Animal
1.5.3 Companion Animal
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Live Attenuated Veterinary Vaccines Revenue Estimates and Forecasts (2021-2032)
2.2 Global Live Attenuated Veterinary Vaccines Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Live Attenuated Veterinary Vaccines Sales Estimates and Forecasts (2021-2032)
2.4 Global Live Attenuated Veterinary Vaccines Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Live Attenuated Veterinary Vaccines Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Live Attenuated Veterinary Vaccines Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Live Attenuated Viral Vaccines: Market Share by Key Manufacturers
3.5.2 Live Attenuated Bacterial Vaccines: Market Share by Key Manufacturers
3.5.3 Other: Market Share by Key Manufacturers
3.6 Global Live Attenuated Veterinary Vaccines Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Live Attenuated Veterinary Vaccines Sales Performance by Type
4.1.1 Global Live Attenuated Veterinary Vaccines Sales Volume by Type (2021-2032)
4.1.2 Global Live Attenuated Veterinary Vaccines Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Live Attenuated Veterinary Vaccines Sales Performance by Dosage Form
4.2.1 Global Live Attenuated Veterinary Vaccines Sales Volume by Dosage Form (2021-2032)
4.2.2 Global Live Attenuated Veterinary Vaccines Revenue by Dosage Form (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Dosage Form (2021-2032)
4.3 Global Live Attenuated Veterinary Vaccines Sales Performance by Vaccine Combination
4.3.1 Global Live Attenuated Veterinary Vaccines Sales Volume by Vaccine Combination (2021-2032)
4.3.2 Global Live Attenuated Veterinary Vaccines Revenue by Vaccine Combination (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Vaccine Combination (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Live Attenuated Veterinary Vaccines Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Live Attenuated Veterinary Vaccines Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Live Attenuated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Live Attenuated Veterinary Vaccines Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Live Attenuated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Live Attenuated Veterinary Vaccines Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Live Attenuated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Live Attenuated Veterinary Vaccines Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Live Attenuated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Live Attenuated Veterinary Vaccines Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Live Attenuated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Live Attenuated Veterinary Vaccines Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.1.4 Merck Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Merck Live Attenuated Veterinary Vaccines Sales by Product in 2025
11.1.6 Merck Live Attenuated Veterinary Vaccines Sales by Application in 2025
11.1.7 Merck Live Attenuated Veterinary Vaccines Sales by Geographic Area in 2025
11.1.8 Merck Live Attenuated Veterinary Vaccines SWOT Analysis
11.1.9 Merck Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.2.4 Zoetis Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Live Attenuated Veterinary Vaccines Sales by Product in 2025
11.2.6 Zoetis Live Attenuated Veterinary Vaccines Sales by Application in 2025
11.2.7 Zoetis Live Attenuated Veterinary Vaccines Sales by Geographic Area in 2025
11.2.8 Zoetis Live Attenuated Veterinary Vaccines SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.3.4 Boehringer Ingelheim Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Live Attenuated Veterinary Vaccines Sales by Product in 2025
11.3.6 Boehringer Ingelheim Live Attenuated Veterinary Vaccines Sales by Application in 2025
11.3.7 Boehringer Ingelheim Live Attenuated Veterinary Vaccines Sales by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Live Attenuated Veterinary Vaccines SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva
11.4.1 Ceva Corporation Information
11.4.2 Ceva Business Overview
11.4.3 Ceva Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.4.4 Ceva Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Live Attenuated Veterinary Vaccines Sales by Product in 2025
11.4.6 Ceva Live Attenuated Veterinary Vaccines Sales by Application in 2025
11.4.7 Ceva Live Attenuated Veterinary Vaccines Sales by Geographic Area in 2025
11.4.8 Ceva Live Attenuated Veterinary Vaccines SWOT Analysis
11.4.9 Ceva Recent Developments
11.5 CAHIC
11.5.1 CAHIC Corporation Information
11.5.2 CAHIC Business Overview
11.5.3 CAHIC Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.5.4 CAHIC Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 CAHIC Live Attenuated Veterinary Vaccines Sales by Product in 2025
11.5.6 CAHIC Live Attenuated Veterinary Vaccines Sales by Application in 2025
11.5.7 CAHIC Live Attenuated Veterinary Vaccines Sales by Geographic Area in 2025
11.5.8 CAHIC Live Attenuated Veterinary Vaccines SWOT Analysis
11.5.9 CAHIC Recent Developments
11.6 HVRI
11.6.1 HVRI Corporation Information
11.6.2 HVRI Business Overview
11.6.3 HVRI Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.6.4 HVRI Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 HVRI Recent Developments
11.7 Ringpu Biology
11.7.1 Ringpu Biology Corporation Information
11.7.2 Ringpu Biology Business Overview
11.7.3 Ringpu Biology Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.7.4 Ringpu Biology Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Ringpu Biology Recent Developments
11.8 Yebio
11.8.1 Yebio Corporation Information
11.8.2 Yebio Business Overview
11.8.3 Yebio Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.8.4 Yebio Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Yebio Recent Developments
11.9 DHN
11.9.1 DHN Corporation Information
11.9.2 DHN Business Overview
11.9.3 DHN Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.9.4 DHN Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 DHN Recent Developments
11.10 WINSUN
11.10.1 WINSUN Corporation Information
11.10.2 WINSUN Business Overview
11.10.3 WINSUN Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.10.4 WINSUN Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 WINSUN Recent Developments
11.11 Elanco
11.11.1 Elanco Corporation Information
11.11.2 Elanco Business Overview
11.11.3 Elanco Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.11.4 Elanco Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Elanco Recent Developments
11.12 Virbac
11.12.1 Virbac Corporation Information
11.12.2 Virbac Business Overview
11.12.3 Virbac Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.12.4 Virbac Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Virbac Recent Developments
11.13 Jinyu Bio-Technology
11.13.1 Jinyu Bio-Technology Corporation Information
11.13.2 Jinyu Bio-Technology Business Overview
11.13.3 Jinyu Bio-Technology Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.13.4 Jinyu Bio-Technology Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Jinyu Bio-Technology Recent Developments
11.14 ChengDu Tecbond
11.14.1 ChengDu Tecbond Corporation Information
11.14.2 ChengDu Tecbond Business Overview
11.14.3 ChengDu Tecbond Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.14.4 ChengDu Tecbond Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 ChengDu Tecbond Recent Developments
11.15 CAVAC
11.15.1 CAVAC Corporation Information
11.15.2 CAVAC Business Overview
11.15.3 CAVAC Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.15.4 CAVAC Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 CAVAC Recent Developments
11.16 Kyoto Biken Laboratories
11.16.1 Kyoto Biken Laboratories Corporation Information
11.16.2 Kyoto Biken Laboratories Business Overview
11.16.3 Kyoto Biken Laboratories Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.16.4 Kyoto Biken Laboratories Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Kyoto Biken Laboratories Recent Developments
11.17 FATRO
11.17.1 FATRO Corporation Information
11.17.2 FATRO Business Overview
11.17.3 FATRO Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.17.4 FATRO Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 FATRO Recent Developments
11.18 Vaksindo
11.18.1 Vaksindo Corporation Information
11.18.2 Vaksindo Business Overview
11.18.3 Vaksindo Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.18.4 Vaksindo Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Vaksindo Recent Developments
11.19 Bio-Labs
11.19.1 Bio-Labs Corporation Information
11.19.2 Bio-Labs Business Overview
11.19.3 Bio-Labs Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.19.4 Bio-Labs Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Bio-Labs Recent Developments
11.20 Avimex Animal Health
11.20.1 Avimex Animal Health Corporation Information
11.20.2 Avimex Animal Health Business Overview
11.20.3 Avimex Animal Health Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.20.4 Avimex Animal Health Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Avimex Animal Health Recent Developments
11.21 MEVAC
11.21.1 MEVAC Corporation Information
11.21.2 MEVAC Business Overview
11.21.3 MEVAC Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.21.4 MEVAC Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 MEVAC Recent Developments
11.22 Biovac
11.22.1 Biovac Corporation Information
11.22.2 Biovac Business Overview
11.22.3 Biovac Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.22.4 Biovac Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Biovac Recent Developments
11.23 Atafen
11.23.1 Atafen Corporation Information
11.23.2 Atafen Business Overview
11.23.3 Atafen Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.23.4 Atafen Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Atafen Recent Developments
11.24 Dyntec
11.24.1 Dyntec Corporation Information
11.24.2 Dyntec Business Overview
11.24.3 Dyntec Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.24.4 Dyntec Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 Dyntec Recent Developments
11.25 RVSRI
11.25.1 RVSRI Corporation Information
11.25.2 RVSRI Business Overview
11.25.3 RVSRI Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.25.4 RVSRI Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 RVSRI Recent Developments
11.26 Medion
11.26.1 Medion Corporation Information
11.26.2 Medion Business Overview
11.26.3 Medion Live Attenuated Veterinary Vaccines Product Models, Descriptions and Specifications
11.26.4 Medion Live Attenuated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Medion Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Live Attenuated Veterinary Vaccines Industry Chain
12.2 Live Attenuated Veterinary Vaccines Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Live Attenuated Veterinary Vaccines Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Live Attenuated Veterinary Vaccines Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Live Attenuated Veterinary Vaccines Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Live Attenuated Veterinary Vaccines Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Vaccine Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Live Attenuated Veterinary Vaccines Revenue by Region (US$ Million), 2021-2026
Table 7. Global Live Attenuated Veterinary Vaccines Revenue by Region (US$ Million), 2027-2032
Table 8. Global Live Attenuated Veterinary Vaccines Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Table 9. Global Live Attenuated Veterinary Vaccines Sales by Region (K Dose), 2021-2026
Table 10. Global Live Attenuated Veterinary Vaccines Sales by Region (K Dose), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Live Attenuated Veterinary Vaccines Sales by Manufacturers (K Dose), 2021-2026
Table 13. Global Live Attenuated Veterinary Vaccines Sales Share by Manufacturers (2021-2026)
Table 14. Global Live Attenuated Veterinary Vaccines Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Live Attenuated Veterinary Vaccines Revenue, 2025
Table 18. Global Live Attenuated Veterinary Vaccines Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Live Attenuated Veterinary Vaccines Average Selling Price (ASP) by Manufacturers (US$/Dose), 2021-2026
Table 20. Key Manufacturers Live Attenuated Veterinary Vaccines Manufacturing Base and Headquarters
Table 21. Global Live Attenuated Veterinary Vaccines Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Live Attenuated Veterinary Vaccines Sales Volume by Type (K Dose), 2021-2026
Table 25. Global Live Attenuated Veterinary Vaccines Sales Volume by Type (K Dose), 2027-2032
Table 26. Global Live Attenuated Veterinary Vaccines Revenue by Type (US$ Million), 2021-2026
Table 27. Global Live Attenuated Veterinary Vaccines Revenue by Type (US$ Million), 2027-2032
Table 28. Global Live Attenuated Veterinary Vaccines Sales Volume by Dosage Form (K Dose), 2021-2026
Table 29. Global Live Attenuated Veterinary Vaccines Sales Volume by Dosage Form (K Dose), 2027-2032
Table 30. Global Live Attenuated Veterinary Vaccines Revenue by Dosage Form (US$ Million), 2021-2026
Table 31. Global Live Attenuated Veterinary Vaccines Revenue by Dosage Form (US$ Million), 2027-2032
Table 32. Global Live Attenuated Veterinary Vaccines Sales Volume by Vaccine Combination (K Dose), 2021-2026
Table 33. Global Live Attenuated Veterinary Vaccines Sales Volume by Vaccine Combination (K Dose), 2027-2032
Table 34. Global Live Attenuated Veterinary Vaccines Revenue by Vaccine Combination (US$ Million), 2021-2026
Table 35. Global Live Attenuated Veterinary Vaccines Revenue by Vaccine Combination (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Live Attenuated Veterinary Vaccines Sales by Application (K Dose), 2021-2026
Table 38. Global Live Attenuated Veterinary Vaccines Sales by Application (K Dose), 2027-2032
Table 39. Live Attenuated Veterinary Vaccines High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Live Attenuated Veterinary Vaccines Revenue by Application (US$ Million), 2021-2026
Table 41. Global Live Attenuated Veterinary Vaccines Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Live Attenuated Veterinary Vaccines Growth Accelerators and Market Barriers
Table 45. North America Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Live Attenuated Veterinary Vaccines Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Live Attenuated Veterinary Vaccines Growth Accelerators and Market Barriers
Table 48. Europe Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Live Attenuated Veterinary Vaccines Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Live Attenuated Veterinary Vaccines Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Live Attenuated Veterinary Vaccines Growth Accelerators and Market Barriers
Table 53. Southeast Asia Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Live Attenuated Veterinary Vaccines Investment Opportunities and Key Challenges
Table 55. Central and South America Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Live Attenuated Veterinary Vaccines Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Live Attenuated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Merck Corporation Information
Table 59. Merck Description and Major Businesses
Table 60. Merck Product Models, Descriptions and Specifications
Table 61. Merck Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 62. Merck Sales Value Proportion by Product in 2025
Table 63. Merck Sales Value Proportion by Application in 2025
Table 64. Merck Sales Value Proportion by Geographic Area in 2025
Table 65. Merck Live Attenuated Veterinary Vaccines SWOT Analysis
Table 66. Merck Recent Developments
Table 67. Zoetis Corporation Information
Table 68. Zoetis Description and Major Businesses
Table 69. Zoetis Product Models, Descriptions and Specifications
Table 70. Zoetis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 71. Zoetis Sales Value Proportion by Product in 2025
Table 72. Zoetis Sales Value Proportion by Application in 2025
Table 73. Zoetis Sales Value Proportion by Geographic Area in 2025
Table 74. Zoetis Live Attenuated Veterinary Vaccines SWOT Analysis
Table 75. Zoetis Recent Developments
Table 76. Boehringer Ingelheim Corporation Information
Table 77. Boehringer Ingelheim Description and Major Businesses
Table 78. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 79. Boehringer Ingelheim Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 80. Boehringer Ingelheim Sales Value Proportion by Product in 2025
Table 81. Boehringer Ingelheim Sales Value Proportion by Application in 2025
Table 82. Boehringer Ingelheim Sales Value Proportion by Geographic Area in 2025
Table 83. Boehringer Ingelheim Live Attenuated Veterinary Vaccines SWOT Analysis
Table 84. Boehringer Ingelheim Recent Developments
Table 85. Ceva Corporation Information
Table 86. Ceva Description and Major Businesses
Table 87. Ceva Product Models, Descriptions and Specifications
Table 88. Ceva Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 89. Ceva Sales Value Proportion by Product in 2025
Table 90. Ceva Sales Value Proportion by Application in 2025
Table 91. Ceva Sales Value Proportion by Geographic Area in 2025
Table 92. Ceva Live Attenuated Veterinary Vaccines SWOT Analysis
Table 93. Ceva Recent Developments
Table 94. CAHIC Corporation Information
Table 95. CAHIC Description and Major Businesses
Table 96. CAHIC Product Models, Descriptions and Specifications
Table 97. CAHIC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. CAHIC Sales Value Proportion by Product in 2025
Table 99. CAHIC Sales Value Proportion by Application in 2025
Table 100. CAHIC Sales Value Proportion by Geographic Area in 2025
Table 101. CAHIC Live Attenuated Veterinary Vaccines SWOT Analysis
Table 102. CAHIC Recent Developments
Table 103. HVRI Corporation Information
Table 104. HVRI Description and Major Businesses
Table 105. HVRI Product Models, Descriptions and Specifications
Table 106. HVRI Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. HVRI Recent Developments
Table 108. Ringpu Biology Corporation Information
Table 109. Ringpu Biology Description and Major Businesses
Table 110. Ringpu Biology Product Models, Descriptions and Specifications
Table 111. Ringpu Biology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Ringpu Biology Recent Developments
Table 113. Yebio Corporation Information
Table 114. Yebio Description and Major Businesses
Table 115. Yebio Product Models, Descriptions and Specifications
Table 116. Yebio Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Yebio Recent Developments
Table 118. DHN Corporation Information
Table 119. DHN Description and Major Businesses
Table 120. DHN Product Models, Descriptions and Specifications
Table 121. DHN Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. DHN Recent Developments
Table 123. WINSUN Corporation Information
Table 124. WINSUN Description and Major Businesses
Table 125. WINSUN Product Models, Descriptions and Specifications
Table 126. WINSUN Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. WINSUN Recent Developments
Table 128. Elanco Corporation Information
Table 129. Elanco Description and Major Businesses
Table 130. Elanco Product Models, Descriptions and Specifications
Table 131. Elanco Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Elanco Recent Developments
Table 133. Virbac Corporation Information
Table 134. Virbac Description and Major Businesses
Table 135. Virbac Product Models, Descriptions and Specifications
Table 136. Virbac Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Virbac Recent Developments
Table 138. Jinyu Bio-Technology Corporation Information
Table 139. Jinyu Bio-Technology Description and Major Businesses
Table 140. Jinyu Bio-Technology Product Models, Descriptions and Specifications
Table 141. Jinyu Bio-Technology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Jinyu Bio-Technology Recent Developments
Table 143. ChengDu Tecbond Corporation Information
Table 144. ChengDu Tecbond Description and Major Businesses
Table 145. ChengDu Tecbond Product Models, Descriptions and Specifications
Table 146. ChengDu Tecbond Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. ChengDu Tecbond Recent Developments
Table 148. CAVAC Corporation Information
Table 149. CAVAC Description and Major Businesses
Table 150. CAVAC Product Models, Descriptions and Specifications
Table 151. CAVAC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. CAVAC Recent Developments
Table 153. Kyoto Biken Laboratories Corporation Information
Table 154. Kyoto Biken Laboratories Description and Major Businesses
Table 155. Kyoto Biken Laboratories Product Models, Descriptions and Specifications
Table 156. Kyoto Biken Laboratories Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. Kyoto Biken Laboratories Recent Developments
Table 158. FATRO Corporation Information
Table 159. FATRO Description and Major Businesses
Table 160. FATRO Product Models, Descriptions and Specifications
Table 161. FATRO Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 162. FATRO Recent Developments
Table 163. Vaksindo Corporation Information
Table 164. Vaksindo Description and Major Businesses
Table 165. Vaksindo Product Models, Descriptions and Specifications
Table 166. Vaksindo Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 167. Vaksindo Recent Developments
Table 168. Bio-Labs Corporation Information
Table 169. Bio-Labs Description and Major Businesses
Table 170. Bio-Labs Product Models, Descriptions and Specifications
Table 171. Bio-Labs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 172. Bio-Labs Recent Developments
Table 173. Avimex Animal Health Corporation Information
Table 174. Avimex Animal Health Description and Major Businesses
Table 175. Avimex Animal Health Product Models, Descriptions and Specifications
Table 176. Avimex Animal Health Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 177. Avimex Animal Health Recent Developments
Table 178. MEVAC Corporation Information
Table 179. MEVAC Description and Major Businesses
Table 180. MEVAC Product Models, Descriptions and Specifications
Table 181. MEVAC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 182. MEVAC Recent Developments
Table 183. Biovac Corporation Information
Table 184. Biovac Description and Major Businesses
Table 185. Biovac Product Models, Descriptions and Specifications
Table 186. Biovac Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 187. Biovac Recent Developments
Table 188. Atafen Corporation Information
Table 189. Atafen Description and Major Businesses
Table 190. Atafen Product Models, Descriptions and Specifications
Table 191. Atafen Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 192. Atafen Recent Developments
Table 193. Dyntec Corporation Information
Table 194. Dyntec Description and Major Businesses
Table 195. Dyntec Product Models, Descriptions and Specifications
Table 196. Dyntec Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 197. Dyntec Recent Developments
Table 198. RVSRI Corporation Information
Table 199. RVSRI Description and Major Businesses
Table 200. RVSRI Product Models, Descriptions and Specifications
Table 201. RVSRI Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 202. RVSRI Recent Developments
Table 203. Medion Corporation Information
Table 204. Medion Description and Major Businesses
Table 205. Medion Product Models, Descriptions and Specifications
Table 206. Medion Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 207. Medion Recent Developments
Table 208. Key Raw Materials Distribution
Table 209. Raw Materials Key Suppliers
Table 210. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 211. Milestones in Production Technology Evolution
Table 212. Distributors List
Table 213. Market Trends and Market Evolution
Table 214. Market Drivers and Opportunities
Table 215. Market Challenges, Risks, and Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources

List of Figures
Figure 1. Live Attenuated Veterinary Vaccines Product Picture
Figure 2. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Live Attenuated Viral Vaccines Product Picture
Figure 4. Live Attenuated Bacterial Vaccines Product Picture
Figure 5. Other Product Picture
Figure 6. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Freeze-Dried Live Attenuated Vaccines Product Picture
Figure 8. Liquid Live Attenuated Vaccines Product Picture
Figure 9. Frozen Live Attenuated Vaccines Product Picture
Figure 10. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Vaccine Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Vaccines Product Picture
Figure 12. Multivalent Vaccines Product Picture
Figure 13. Combination Vaccines Product Picture
Figure 14. Global Live Attenuated Veterinary Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Farm Animal
Figure 16. Companion Animal
Figure 17. Live Attenuated Veterinary Vaccines Report Years Considered
Figure 18. Global Live Attenuated Veterinary Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 19. Global Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 20. Global Live Attenuated Veterinary Vaccines Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share by Region (2021-2032)
Figure 22. Global Live Attenuated Veterinary Vaccines Sales (K Dose), 2021-2032
Figure 23. Global Live Attenuated Veterinary Vaccines Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Figure 24. Global Live Attenuated Veterinary Vaccines Sales Market Share by Region (2021-2032)
Figure 25. Top 5 and Top 10 Manufacturers Live Attenuated Veterinary Vaccines Sales Volume Market Share in 2025
Figure 26. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. Live Attenuated Viral Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 29. Live Attenuated Bacterial Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 30. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Global Live Attenuated Veterinary Vaccines Sales Volume-Based Market Share by Type (2021-2032)
Figure 32. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Live Attenuated Veterinary Vaccines ASP by Type (US$/Dose), 2021-2032
Figure 34. Global Live Attenuated Veterinary Vaccines Sales Volume-Based Market Share by Dosage Form (2021-2032)
Figure 35. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share by Dosage Form (2021-2032)
Figure 36. Global Live Attenuated Veterinary Vaccines ASP by Dosage Form (US$/Dose), 2021-2032
Figure 37. Global Live Attenuated Veterinary Vaccines Sales Volume-Based Market Share by Vaccine Combination (2021-2032)
Figure 38. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share by Vaccine Combination (2021-2032)
Figure 39. Global Live Attenuated Veterinary Vaccines ASP by Vaccine Combination (US$/Dose), 2021-2032
Figure 40. Global Live Attenuated Veterinary Vaccines Sales Market Share by Application (2021-2032)
Figure 41. Global Live Attenuated Veterinary Vaccines Revenue-Based Market Share by Application (2021-2032)
Figure 42. Global Live Attenuated Veterinary Vaccines ASP by Application (US$/Dose), 2021-2032
Figure 43. North America Live Attenuated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 44. North America Live Attenuated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 45. North America Top 5 Manufacturers Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 46. North America Live Attenuated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 47. North America Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 48. US Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 49. Canada Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 50. Mexico Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 51. Europe Live Attenuated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 52. Europe Live Attenuated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 53. Europe Top 5 Manufacturers Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 54. Europe Live Attenuated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 55. Europe Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 56. Germany Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 57. France Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 58. U.K. Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 59. Italy Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 60. Russia Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 61. Asia-Pacific Live Attenuated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 62. Asia-Pacific Live Attenuated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 63. Asia-Pacific Top 8 Manufacturers Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 64. Asia-Pacific Live Attenuated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 65. Asia-Pacific Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 66. Indonesia Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 67. Japan Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 68. South Korea Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 69. China Taiwan Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 70. India Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 71. Central and South America Live Attenuated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 72. Central and South America Live Attenuated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 73. Central and South America Top 5 Manufacturers Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 74. Central and South America Live Attenuated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 75. Central and South America Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 76. Brazil Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 77. Argentina Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 78. Middle East, and Africa Live Attenuated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 79. Middle East and Africa Live Attenuated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 80. Middle East and Africa Top 5 Manufacturers Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 81. Middle East and Africa Live Attenuated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 82. Middle East and Africa Live Attenuated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 83. GCC Countries Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 84. Turkey Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 85. Egypt Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 86. South Africa Live Attenuated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 87. Live Attenuated Veterinary Vaccines Industry Chain Mapping
Figure 88. Regional Live Attenuated Veterinary Vaccines Manufacturing Base Distribution (%)
Figure 89. Global Live Attenuated Veterinary Vaccines Production Market Share by Region (2021-2032)
Figure 90. Live Attenuated Veterinary Vaccines Production Process
Figure 91. Regional Live Attenuated Veterinary Vaccines Production Cost Structure
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed